Aspire Biopharma Holdings, Inc.
ASBP
$0.4871
-$0.0205-4.04%
NASDAQ
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 541.20K | 356.40K | 349.80K | 281.40K | -- |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 579.70K | 402.60K | 396.00K | 340.50K | -- |
| Operating Income | -579.70K | -402.60K | -396.00K | -340.50K | -- |
| Income Before Tax | -579.70K | -402.60K | -396.00K | -340.50K | -- |
| Income Tax Expenses | 1.50K | 500.00 | 500.00 | 500.00 | -- |
| Earnings from Continuing Operations | -0.58 | -0.40 | -0.40 | -0.34 | -- |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -581.20K | -403.10K | -396.50K | -341.00K | -- |
| EBIT | -579.70K | -402.60K | -396.00K | -340.50K | -- |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | -- |
| Average Basic Shares Outstanding | 1.33B | 886.32M | 443.00M | 443.00M | -- |
| Average Diluted Shares Outstanding | 1.77B | 1.33B | 886.00M | 443.00M | -- |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |